Joseph R Testa

发表

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

Andrew K Godwin, A. Godwin, J. Testa, 2004, Oncogene.

ArgBP2γ Interacts with Akt and p21-activated Kinase-1 and Promotes Cell Survival*

Satoshi Kaneko, S. Nicosia, J. Cheng, 2005, Journal of Biological Chemistry.

Cancer stem‐like cell properties are regulated by EGFR/AKT/β–catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma

Ying Liu, Gong Zhang, Kai-Tai Yao, 2013, The FEBS journal.

BAP1 and cancer

Thomas Krausz, H. Pass, J. Testa, 2013, Nature Reviews Cancer.

NF2: The wizardry of merlin

Jonathan Chernoff, J. Testa, J. Chernoff, 2003, Genes, chromosomes & cancer.

ArgBP2γ interacts with Akt and p21-activated kinase-1 and promotes cell survival.

Satoshi Kaneko, S. Nicosia, J. Cheng, 2016, The Journal of Biological Chemistry.

Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2

Erica A Golemis, Satoshi Tanno, Steven W. Johnson, 1999, Oncogene.

Diverse mechanisms of AKT pathway activation in human malignancy.

J. Testa, M. Cheung, Joseph R Testa, 2013, Current cancer drug targets.

The pathogenesis of mesothelioma.

J. Testa, R. Kratzke, M. Carbone, 2002, Seminars in oncology.

Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin

Arti Shukla, H. Pass, J. Testa, 2010, Molecular Cancer.

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.

J. Testa, Y. Mitsuuchi, B. Balsara, 2004, Carcinogenesis.

Perturbations of the AKT signaling pathway in human cancer

J. Testa, Deborah A Altomare, Joseph R Testa, 2005, Oncogene.